PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery
- 8 November 2017
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 52 (1) , 110-118
Abstract
Objective: To determine the diagnostic performance of two‐dimensional (2D) ultrasound parameters, three‐dimensional (3D) power Doppler and contrast‐enhanced indices in detecting residual disease in locally advanced cervical cancer patients triaged to neoadjuvant treatment followed by radical surgery.Methods: Between October 2010 and June 2014, we screened 108 women with histologically documented locally advanced cervical cancer Stage IB2–IVA, of whom 88 were included in the final analysis. 2D ultrasound parameters, 3D power Doppler and contrast‐ultrasound parameters were assessed 5 weeks after the end of neoadjuvant chemoradiation therapy. The pathological response was defined as complete (absence of any residual tumor after treatment) or partial (including microscopic and/or macroscopic residual tumor at pathology examination). The two response groups were compared and receiver–operating characteristics (ROC) curves generated to determine the best cut‐off value of sonographic tumor diameter to predict residual disease. Histology was considered as reference.Results: Complete pathological response to chemoradiation was observed in 40 (45.5%) patients and partial response in 48 (54.5%). The presence of residual disease, as confirmed at pathology examination, was detected by 2D grayscale ultrasound with a sensitivity of 64.6% and specificity of 65%. Color Doppler examination in the cases with lesions visualized on grayscale imaging detected the presence of residual disease, confirmed at pathology, with a sensitivity of 87.1% and specificity of 21.4%. The best area under the ROC curve (0.817) was for the detection of pathological residual disease of at least 6 mm in diameter, using a cut‐off value of 12 mm for the largest tumor diameter assessed using 2D grayscale ultrasound (sensitivity, 95%; specificity, 70.6%). Neither 3D vascular indices nor contrast‐ultrasound parameters obtained for lesions suspected at ultrasound following chemoradiation differed significantly between patients with histological complete and those with partial response.Conclusions: Our results show that grayscale and color Doppler ultrasound have a low level of diagnostic performance in detecting residual disease after neoadjuvant chemoradiation in patients with locally advanced cervical cancer. The best performance was achieved in detection of macroscopic (≥ 6 mm) residual disease. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.Keywords
This publication has 25 references indexed in Scilit:
- Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervixUltrasound in Obstetrics & Gynecology, 2010
- Three‐dimensional power Doppler angiography in endometrial cancer: correlation with tumor characteristicsUltrasound in Obstetrics & Gynecology, 2010
- Prognostic Factors and Morbidities After Completion Surgery in Patients Undergoing Initial Chemoradiation Therapy for Locally Advanced Cervical CancerThe Oncologist, 2010
- Results of Surgery After Concurrent Chemoradiotherapy in Advanced Cervical CancerInternational Journal of Gynecological Cancer, 2010
- Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancerUltrasound in Obstetrics & Gynecology, 2009
- Classification of radical hysterectomyThe Lancet Oncology, 2008
- Neoadjuvant chemotherapy in cervical cancer: a 67 patients experienceInternational Journal of Gynecological Cancer, 2006
- Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinomaActa Obstetricia et Gynecologica Scandinavica, 2004
- Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) groupUltrasound in Obstetrics & Gynecology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000